Lung Cancer
Volume 46, Issue 2 , Pages 255-261 , November 2004

Effect of gefitinib (‘Iressa’, ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer

  • Katsuyuki Hotta

      Affiliations

    • Department of Hematology, Oncology and Respiratory Medicine, Graduate School of Medicine and Dentistry, Okayama University, 2-5-1 Shikata-cho, Okayama 700-8558, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 86 235 7227; fax: +81 86 232 8226.
    • ,
  • Katsuyuki Kiura

      Affiliations

    • Department of Respiratory Medicine, Okayama University Hospital, 2-5-1 Shikata-cho, Okayama 700-8558, Japan
    • ,
  • Hiroshi Ueoka

      Affiliations

    • Department of Hematology, Oncology and Respiratory Medicine, Graduate School of Medicine and Dentistry, Okayama University, 2-5-1 Shikata-cho, Okayama 700-8558, Japan
    • ,
  • Masahiro Tabata

      Affiliations

    • Department of Respiratory Medicine, Okayama University Hospital, 2-5-1 Shikata-cho, Okayama 700-8558, Japan
    • ,
  • Keiichi Fujiwara

      Affiliations

    • Department of Respiratory Medicine, Okayama University Hospital, 2-5-1 Shikata-cho, Okayama 700-8558, Japan
    • ,
  • Toshiyuki Kozuki

      Affiliations

    • Department of Hematology, Oncology and Respiratory Medicine, Graduate School of Medicine and Dentistry, Okayama University, 2-5-1 Shikata-cho, Okayama 700-8558, Japan
    • ,
  • Toshiaki Okada

      Affiliations

    • Department of Hematology, Oncology and Respiratory Medicine, Graduate School of Medicine and Dentistry, Okayama University, 2-5-1 Shikata-cho, Okayama 700-8558, Japan
    • ,
  • Akiko Hisamoto

      Affiliations

    • Department of Hematology, Oncology and Respiratory Medicine, Graduate School of Medicine and Dentistry, Okayama University, 2-5-1 Shikata-cho, Okayama 700-8558, Japan
    • ,
  • Mitsune Tanimoto

      Affiliations

    • Department of Hematology, Oncology and Respiratory Medicine, Graduate School of Medicine and Dentistry, Okayama University, 2-5-1 Shikata-cho, Okayama 700-8558, Japan

Received 30 December 2003 ,Revised 15 April 2004 ,Accepted 19 April 2004.

References 

  1. Stanley K, Stjernsward J. Lung cancer—a worldwide health problem. Chest. 1989;96(Suppl 1):1S–5S
  2. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311: 899–909.
  3. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al.  Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New Engl. J. Med. 2002;346:92–98
  4. Rusch V, Baselga J, Cordon-Cardo C, Orazem J, Zaman M, Hoda S, et al.  Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res. 1993;53:2379–2385
  5. Volm M, Rittgen W, Drings P. Prognostic value of ERBB-1, VEGF, cyclin A., FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br. J. Cancer. 1998;77:663–669
  6. Lawrence DS, Niu J. Protein kinase inhibitors: the tyrosine-specific protein kinases. Pharmacol. Ther. 1998;77:81–114
  7. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al.  Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 2003;21:2237–2246
  8. Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, et al  Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. A randomized trial. JAMA. 2003;290:2149–2158
  9. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al.  New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer. Inst. 2000;92:205–216
  10. Shimoyama M. The Japanese edition of the National Cancer Institute Common Toxicity Criteria. Gan to Kagaku Ryoho. 1999;26:1084–1144 [Japanese]
  11. Fujiwara K, Kiura K, Ueoka H, Tabata M, Hamasaki S, Tanimoto M. Dramatic effect of ZD1839 (‘Iressa’) in a patient with advanced non-small-cell lung cancer and poor performance status. Lung Cancer. 2003;40:73–76
  12. Cappuzzo F, Ardizzoni A, Soto-Parra H, Gridelli C, Maione P, Tiseo M, et al  Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC). Lung Cancer. 2003;41:227–231
  13. Heimberger AB, Learn CA, Archer GE, McLendon RE, Chewning TA, Tuck FL, et al.  Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (Iressa). Clin. Cancer Res. 2002;8:3496–3502
  14. AstraZeneca data on file.
  15. Hortobagyi GN. Developments in chemotherapy of breast cancer. Cancer. 2000;88(Suppl 12):3073–3079
  16. Manley PW, Cowan-Jacob SW, Buchdunger E, Fabbro D, Fendrich G, Furet P, et al.  Imatinib: a selective tyrosine kinase inhibitor. Eur. J. Cancer. 2002;38(Suppl 5):S19–27
  17. Shah NT, Miller VA, Kris MG, Patel J, Venkatraman E, Benporat L, et al.  Bronchioalveolar histology and smoking history predict response to gefitinib. Proc. Am. Soc. Clin. Oncol. 2003;22:628; [abstract 2524]
  18. Gridelli C, Maione P, Castaldo V, Rossi A. Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer. Br. J. Cancer. 2003;89:1827–1829

PII: S0169-5002(04)00214-4

doi: 10.1016/j.lungcan.2004.04.036

Lung Cancer
Volume 46, Issue 2 , Pages 255-261 , November 2004

Article Tools